Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Therapeutics for Memory and Cognition Disorders
Market Study
Published: April 2009
Pages: 165
Tables: 50
From: GBP 3031.00 Buy Now!
Research from: Business Communications Company Inc.
Sector: Prescription Medicines
This Report:
The global market for therapeutics for memory and cognitive disorders will increase from $6.7 billion in 2008 to an estimated $7.3 billion by the end of 2009. It should reach almost $36.0 billion in 2014, a compound annual growth rate (CAGR) of 37.5%.
Treatments for Alzheimer’s disease have the largest share of the market, worth $3.9 billion in 2008. This is expected to increase to $4.4 billion in 2009 and $22.4 billion in 2014, for a CAGR of 38.8%.
Treatments for MCI/AACI have the second largest market share, generating $1.6 billion in 2008 and an estimated $1.7 billion in 2009. This should increase at a CAGR of 33.9% to reach $7.1 billion in 2014. INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study is to determine the current status of the therapeutics and treatments for memory and cognition deficits and assess the growth potential of this area over a 5-year period from 2009 to 2014. We were particularly interested in how demographics are impacting the development efforts being undertaken currently and how memory/cognition is evolving into a therapeutic focus in its own right.
Our key objective is to present a comprehensive analysis of the current pipeline, the market and forecast for memory/cognition therapeutics and the key factors that will influence this therapeutic area in the next few years.
REASONS FOR DOING THIS STUDY
As the mechanisms of the central nervous system become more elucidated, the opportunity for treating memory/cognition deficits and related diseases is coming to the forefront. This study aims to quantify where this market is heading and where the opportunities may lie.
SCOPE OF REPORT
Although there are several modes of treating memory and cognitive deficiency, the scope of this report is on the pharmaceutical segment. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients and the medical community. It will be of interest also to suppliers of products and services to this market area.
INTENDED AUDIENCE
The intended audience for this report is the pharmaceutical and biotechnology industries, as well as the medical industry which treats patients in these areas.
METHODOLOGY
Both primary and secondary research methods were used in preparing this study. BCC presents an analysis, by each disease area, of a number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2009 and 2014.
INFORMATION SOURCES
BCC surveyed approximately fifty companies to obtain data for this study. Included were drug development companies and medical professionals. We also spoke with patients affected by memory and cognition diseases. In addition, we compiled data from current financial and trade information and government sources.
The global market for therapeutics for memory and cognitive disorders will increase from $6.7 billion in 2008 to an estimated $7.3 billion by the end of 2009. It should reach almost $36.0 billion in 2014, a compound annual growth rate (CAGR) of 37.5%.
Treatments for Alzheimer’s disease have the largest share of the market, worth $3.9 billion in 2008. This is expected to increase to $4.4 billion in 2009 and $22.4 billion in 2014, for a CAGR of 38.8%.
Treatments for MCI/AACI have the second largest market share, generating $1.6 billion in 2008 and an estimated $1.7 billion in 2009. This should increase at a CAGR of 33.9% to reach $7.1 billion in 2014. INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study is to determine the current status of the therapeutics and treatments for memory and cognition deficits and assess the growth potential of this area over a 5-year period from 2009 to 2014. We were particularly interested in how demographics are impacting the development efforts being undertaken currently and how memory/cognition is evolving into a therapeutic focus in its own right.
Our key objective is to present a comprehensive analysis of the current pipeline, the market and forecast for memory/cognition therapeutics and the key factors that will influence this therapeutic area in the next few years.
REASONS FOR DOING THIS STUDY
As the mechanisms of the central nervous system become more elucidated, the opportunity for treating memory/cognition deficits and related diseases is coming to the forefront. This study aims to quantify where this market is heading and where the opportunities may lie.
SCOPE OF REPORT
Although there are several modes of treating memory and cognitive deficiency, the scope of this report is on the pharmaceutical segment. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients and the medical community. It will be of interest also to suppliers of products and services to this market area.
INTENDED AUDIENCE
The intended audience for this report is the pharmaceutical and biotechnology industries, as well as the medical industry which treats patients in these areas.
METHODOLOGY
Both primary and secondary research methods were used in preparing this study. BCC presents an analysis, by each disease area, of a number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2009 and 2014.
INFORMATION SOURCES
BCC surveyed approximately fifty companies to obtain data for this study. Included were drug development companies and medical professionals. We also spoke with patients affected by memory and cognition diseases. In addition, we compiled data from current financial and trade information and government sources.